Uriflow Safety in Pregnancy
Uriflow (sodium phosphate) is classified as Pregnancy Category C and should only be given to pregnant women if clearly needed, as no adequate studies have been conducted to establish its safety during pregnancy. 1
Critical Safety Information
The FDA drug label for Uriflow explicitly states that animal reproduction studies have not been conducted with sodium phosphate, and it is unknown whether this medication can cause fetal harm when administered to pregnant women or affect reproductive capacity 1. This places it in the cautious category where risk cannot be ruled out.
Key Considerations for Use in Pregnancy
Pregnancy Category C Implications
- No controlled human studies exist to demonstrate safety
- The medication should only be used when potential benefits justify potential risks to the fetus
- Clinical judgment must weigh the necessity of treatment against unknown fetal risks 1
Additional Safety Concerns
Aluminum toxicity warning: Uriflow contains aluminum that may reach toxic levels with prolonged administration, particularly concerning for patients with impaired kidney function 1. While this warning primarily targets premature neonates receiving parenteral administration, it raises additional concerns about use during pregnancy when fetal kidney development is ongoing.
Electrolyte disturbances: The medication can cause:
- Reduction in serum calcium levels
- Hypocalcemic tetany if infused too rapidly
- Sodium retention in patients with diminished renal function 1
Clinical Decision Framework
Given the lack of safety data and Pregnancy Category C classification, alternative treatments should be strongly considered first for any urological condition during pregnancy. If Uriflow is being considered for urinary tract issues:
- For asymptomatic bacteriuria in pregnancy: Treatment is indicated, but safer alternatives with established pregnancy safety profiles (such as nitrofurantoin, cephalosporins, or fosfomycin) should be used instead 2, 3
- For symptomatic UTIs: First-line agents with better-established safety profiles are available 3
Regarding Availability in the Philippines
While one research study mentions Uriflow as an herbal anti-urolithiatic formulation containing Tribulus terrestris 4, this appears to reference a different product formulation than the FDA-labeled sodium phosphate injection. Clarification of the specific product formulation available in the Philippines is essential, as herbal formulations would have entirely different safety considerations than pharmaceutical sodium phosphate.
The bottom line: Uriflow (sodium phosphate) should be avoided during pregnancy unless no safer alternatives exist and the clinical situation is urgent enough to justify unknown fetal risks.